{
    "clinical_study": {
        "@rank": "126022", 
        "arm_group": [
            {
                "arm_group_label": "Cypher group", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Xience group", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Pravastatin group", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Atorvastatin group", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is a prospective open-labeled, randomized study to compare the neointimal\n      coverage at 3 months and 12 months and its serial changes between 3 months and 12 months\n      according to the implanted DES and evaluate the serial changes in the proximal portions of 3\n      epicardial coronary artery and left main artery including the assessment of fibrous cap\n      thickness and lipid pool for vulnerable plaques by OCT. In addition, the investigators will\n      compare the changes such as plaques and neointimal coverage from serial OCT follow-up\n      according to the different statin strategy."
        }, 
        "brief_title": "Serial EValuation of multiplE Coronary Artery Diseases by an Optical Coherence Tomography; Assessment of the Changes of de Novo Lesions and Comparisons of Neointimal Coverage Between Xience Prime\u00ae Versus Cypher SelectTM Stents; SEVEN-Xience Study", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Multi-vessel Diseases, Angina", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient is \u2265 20 years old\n\n          -  Patients with typical angina who are considered for coronary revascularization.\n\n          -  Multi-vessel diseases: more than 2 significant coronary de novo lesions (> 70% by\n             quantitative angiographic analysis); one of the target lesions is the most\n             significant tight stenotic lesion causing the ischemic symptom and requiring the\n             immediate revascularization but the others are significant but non-tight lesions to\n             be delayed or observed for 3 months and not requiring immediate PCI for the complete\n             revascularization of all coronary arteries.\n\n        Exclusion Criteria:\n\n          -  ST-elevation MI\n\n          -  Cardiogenic shock or hemodynamically unstable status\n\n          -  Lesions requiring the immediate complete revascularization of all coronary stenotic\n             lesions\n\n          -  Contraindication to anti-platelet agents\n\n          -  Treated with any DES within 6 months at other vessel\n\n          -  Creatinine level \u2265 2.0 mg/dL or ESRD\n\n          -  Severe hepatic dysfunction (3 times normal reference values)\n\n          -  Pregnant women or women with potential childbearing\n\n          -  Life expectancy 1 year\n\n          -  Complex lesion morphologies (bifurcation lesions treated with 2-stent techniques,\n             untreated significant unprotected left main diseases, chronic total occlusion,\n             in-stent restenosis, and vein graft lesion)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01856374", 
            "org_study_id": "1-2010-0052"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cypher group", 
                "description": "Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; Xience Prime\u00ae  vs. Cypher SelectTM and pravastatin 20mg vs. atorvastatin 40mg.", 
                "intervention_name": "Sirolimus-eluting stent (Cypher SelectTM, Cordis, Miami, FL)", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Xience group", 
                "description": "Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; Xience Prime\u00ae  vs. Cypher SelectTM and pravastatin 20mg vs. atorvastatin 40mg.", 
                "intervention_name": "Everolimus-eluting stent(Xience Prime\u00ae, Abbott Vascular, Santa Claea, CA)", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Pravastatin group", 
                "description": "2x2 randomization by the treatment of dyslipidemia (In patients of dyslipidemia: pravastatin 20mg/day vs. atorvastatin 40mg and the types of the implanted cypher vs xience.", 
                "intervention_name": "Pravastatin 20mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Atorvastatin group", 
                "description": "2x2 randomization by the treatment of dyslipidemia (In patients of dyslipidemia: pravastatin 20mg/day vs. atorvastatin 40mg and the types of the implanted cypher vs xience.", 
                "intervention_name": "Atorvastatin 40mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Sirolimus", 
                "Everolimus", 
                "Atorvastatin", 
                "Pravastatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 16, 2013", 
        "location": {
            "contact": {
                "email": "mkhong61@yuhs.ac", 
                "last_name": "Myeong-Ki Hong, MD, PhD", 
                "phone": "82-2-2228-8460"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "120-752"
                }, 
                "name": "Severance Hospital"
            }, 
            "investigator": {
                "last_name": "Myeong-Ki Hong, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "4", 
        "overall_contact": {
            "email": "mkhong61@yuhs.ac", 
            "last_name": "Myeong-Ki Hong, MD, PhD", 
            "phone": "82-2-2228-8460"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Neointimal coverage means percentage of uncovered struts on OCT. The percentages of uncovered struts were compared between EES and SES.", 
            "measure": "neointimal coverage according to the implanted DES; Xience vs. Cypher", 
            "safety_issue": "No", 
            "time_frame": "up to 12month after stent implantation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01856374"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Yonsei University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yonsei University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}